Keyphrases
Cholangiocarcinoma
100%
Sulfatide
100%
Epithelial-mesenchymal Transition
100%
Cholangiocarcinoma Cell Line
100%
Effective Treatment
20%
Negative Effects
20%
Barrier Function
20%
Effects on Growth
20%
Cell Adhesion
20%
Cancer Cell Lines
20%
Western Countries
20%
Novel Therapeutic Targets
20%
New Drug Targets
20%
Plasma Membrane
20%
Increased Incidence
20%
Cancer Types
20%
Transepithelial Electrical Resistance
20%
Early Symptoms
20%
Proliferative Activity
20%
Protein Trafficking
20%
Biliary Tract Cancer
20%
Lipid Rafts
20%
Genetic Targeting
20%
Biliary Tract
20%
Glycolytic Activity
20%
Liver Malignancy
20%
Clonogenic Activity
20%
Proliferation Activity
20%
CRISPR-Cas9 System
20%
Bile Duct Cancer
20%
Cholangiocarcinoma Cells
20%
DepMap
20%
Sulfonolipid
20%
Identity Function
20%
INIS
cancer
100%
capacity
100%
comparative evaluations
66%
synthesis
66%
biliary tract
66%
levels
33%
liver
33%
increasing
33%
symptoms
33%
malignancies
33%
losses
33%
barriers
33%
proteins
33%
enzymes
33%
membranes
33%
genetics
33%
growth
33%
plasma
33%
proliferation
33%
adhesion
33%
lipids
33%
permeability
33%
bile ducts
33%
Immunology and Microbiology
Hepatobiliary System
100%
Epithelial Mesenchymal Transition
100%
Cholangiocarcinoma Cell Line
100%
Cell Membrane
50%
Cell Adhesion
50%
Bile Duct
50%
Cancer Cell Line
50%
Transepithelial Resistance
50%
Lipid Raft
50%
Protein Targeting
50%
CRISPR/Cas9
50%
Medicine and Dentistry
Cholangiocarcinoma
100%
Mesenchymal-Epithelial Transition
100%
Sulfatide
100%
Cholangiocarcinoma Cell Line
100%
Malignant Neoplasm
16%
Cancer
16%
Bile Duct Cancer
16%
Cell Membrane
16%
Hepatobiliary System
16%
Cell Adhesion
16%
Cancer Cell Line
16%
Biliary Tract Cancer
16%
Protein Targeting
16%
Lipid Raft
16%
Clustered Regularly Interspaced Short Palindromic Repeat
16%
Cas9
16%
Biochemistry, Genetics and Molecular Biology
Mesenchymal-Epithelial Transition
100%
Sulfatide
100%
Genetics
16%
Cell Membrane
16%
Enzyme
16%
Cancer Cell
16%
Cell Adhesion
16%
Lipid Raft
16%
Transepithelial Resistance
16%
CRISPR/Cas9
16%
Protein Targeting
16%